Search

Your search keyword '"Anwer, Faiz"' showing total 1,591 results
Start Over Author "Anwer, Faiz" Search Limiters Academic (Peer-Reviewed) Journals
1,591 results on '"Anwer, Faiz"'

3. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

Author

Dima, Danai, Abdallah, Al-Ola, Davis, James A., Awada, Hussein, Goel, Utkarsh, Rashid, Aliya, DeJarnette, Shaun, Anwer, Faiz, Shune, Leyla, Raza, Shahzad, Mahmoudjafari, Zahra, Williams, Louis, Faiman, Beth, McGuirk, Joseph P., Sauter, Craig S., Ahmed, Nausheen, Khouri, Jack, and Hashmi, Hamza

Published
2024
Full Text
View/download PDF

17. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience

Author

Khouri, Jack, Dima, Danai, Li, Hong, Hansen, Doris, Sidana, Surbhi, Shune, Leyla, Anwer, Faiz, Sborov, Douglas, Wagner, Charlotte, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter, Peres, Lauren, Hovanky, Vanna, Simmons, Gary, Williams, Louis, Raza, Shahzad, Afrough, Aimaz, Anderson, Larry D., Jr, Ferreri, Christopher, Hashmi, Hamza, Davis, James, McGuirk, Joseph, Goldsmith, Scott, Borogovac, Azra, Lin, Yi, Midha, Shonali, Nadeem, Omar, Locke, Frederick L., Baz, Rachid, Hamilton, Betty, Alsina, Melissa, Sauter, Craig, Patel, Krina, and Kaur, Gurbakhash

Published
2024
Full Text
View/download PDF

18. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

Author

Lin, Cindy Hsin-Ti, primary, Tariq, Muhammad Junaid, additional, Ullah, Fauzia, additional, Sannareddy, Aishwarya, additional, Khalid, Farhan, additional, Abbas, Hasan, additional, Bader, Abbas, additional, Samaras, Christy, additional, Valent, Jason, additional, Khouri, Jack, additional, Anwer, Faiz, additional, Raza, Shahzad, additional, and Dima, Danai, additional

Published
2024
Full Text
View/download PDF

19. Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma.

Author

Basali, Diana, primary, Zureigat, Hadil, additional, Nurse, Daniel Paul, additional, Elmaleh, Hassan, additional, Batah, Heya, additional, Adcock, Bridget, additional, Wei, Wei, additional, Dima, Danai, additional, Valent, Jason Neil, additional, Anwer, Faiz, additional, Samaras, Christy Joy, additional, Khouri, Jack, additional, Williams, Louis, additional, Raza, Shahzad, additional, van Heeckeren, Willem Jan, additional, and Mazzoni, Sandra Ann, additional

Published
2024
Full Text
View/download PDF

20. Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review.

Author

Wesson, William, primary, Ayoobkhan, Fathima Shehnaz, additional, Mahmoudjafari, Zahra, additional, Mushtaq, Muhammad Umair, additional, Abdallah, Al-Ola A., additional, Sun, Weijing, additional, Anwer, Faiz, additional, Doolittle, Gary C., additional, McGuirk, Joseph, additional, Al-Rajabi, Raed Moh'd Taiseer, additional, Baranda, Joaquina Celebre, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

21. Trends in hospice utilization and place of death preferences in multiple myeloma-related deaths from 2003 to 2020: Analysis of CDC Wonder database.

Author

Faisal, Muhammad Salman, primary, Sukaina, Mahnoor, additional, Mishra, Rahul, additional, Khosla, Atulya Aman, additional, Batra, Nitya, additional, Kumar, Madhan Srinivasan, additional, Soror, Noha, additional, Ahmad, Zain Ishtiaq, additional, Jatwani, Karan, additional, and Anwer, Faiz, additional

Published
2024
Full Text
View/download PDF

27. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma.

Author

Paul, Barry, Anwer, Faiz, Raza, Shahzad, Mammadzadeh, Aytaj, Khasawneh, Bayan, Shatnawi, Sara, McGuirk, Joseph, Ahmed, Nausheen, Mahmoudjafari, Zahra, Mushtaq, Muhammad, Abdallah, Al-Ola, and Atrash, Shebli

Subjects
*THERAPEUTIC use of antineoplastic agents, *MULTIPLE myeloma diagnosis, *THERAPEUTIC use of monoclonal antibodies, *MULTIPLE myeloma, *DRUG toxicity, *DRUG side effects, *ANTINEOPLASTIC agents, *META-analysis, *DESCRIPTIVE statistics, *PROGRESSION-free survival, *CONFIDENCE intervals, *INDUCTION chemotherapy, *OVERALL survival
Abstract

Simple Summary: Induction regimens using 4-drugs for patients with newly diagnosed multiple myeloma have shown impressive results in multiple trials. However, trials of 4-drug regimens typically use a 3-drug regimen as their comparator, which limits our ability to determine whether the benefit is from the specific combination of drugs or just the addition of more agents. We performed a meta-analysis to compare all trials that compared 4-drug to 3-drug regimens and found that the addition of an anti-CD38 antibody (daratumumab or isatuximab) resulted in improved responses, while 4-drug regimens without an anti-CD38 antibody performed similarly to 3-drug regimens. While the addition of an anti-CD38 antibody led to increased adverse effects, these were predominantly mild and easily managed. These data suggest that an anti-CD38 antibody should be part of all 4-drug induction regimens for newly diagnosed myeloma patients. The use of 4-drug induction regimens for treatment naïve newly diagnosed multiple myeloma (NDMM) is associated with improved depth of response and progression-free survival (PFS). However, head-to-head trials of 4-drug combinations are lacking, and instead, these regimens are typically compared to 3-drug backbones; limiting the ability to discern whether any additional benefit (or toxicity) is simply additive or represents a synergy (or interaction). We conducted a meta-analysis of phase 2 and phase 3 clinical trials that randomized treatment naïve NDMM patients to either a 4-drug or 3-drug induction regimen. We included 11 trials which represented 6509 unique patients. PFS for all trials in the meta-analysis was 54 months with a 4-drug induction and 8.9 months with a 3-drug induction (HR: 0.49; 95% CI: 0.45; 0.54), but there was no benefit to using a 4-drug induction that did not include an anti-CD38 antibody (PFS 4-drug 8.1 months, PFS 3-drug 8.0 months; HR 0.95; 95% CI 0.86; 1.06). Adverse events were more frequent with the quadruplet regimens but were predominately mild. High-grade (≥3) adverse events (AEs) that were more common with 4-drug regimens were infections (RR: 1.34; 95% CI 1.17; 1.54) and thrombocytopenia (RR: 1.39; 95% CI 1.12; 1.74). This study suggests that 4-drug induction regimens which include an anti-CD38 antibody improve efficacy although with additional toxicity in NDMM patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.

Author

Dima, Danai, Hughes, Michael, Orland, Mark, Ullah, Fauzia, Goel, Utkarsh, Anwer, Faiz, Raza, Shahzad, Mazzoni, Sandra, Bhutani, Divaya, Williams, Louis, Lentzsch, Suzanne, Samaras, Christy, Valent, Jason, Chakraborty, Rajshekhar, and Khouri, Jack

Subjects
OVERALL survival, FAILURE (Psychology), SALVAGE therapy, TREATMENT failure, CARDIAC patients
Abstract

Background: Daratumumab's incorporation in the upfront treatment of light chain (AL) amyloidosis has led to daratumumab (dara) refractoriness early in disease course. Patients who experience relapse or have suboptimal response to dara-based-therapy, have limited options. Objective: This study aimed to evaluate the outcomes of venetoclax-based therapy in t(11;14) positive AL patients who previously failed dara. Methods: Thirty-one patients with AL were included in this bi-institutional retrospective analysis. Results: Dara failure was due to inadequate response in 20 (65%) patients, haematologic relapse in 7 (22%), and both haematologic plus organ relapse in 4 (13%). Overall haematologic response rate to venetoclax-based therapy was 97%, with ≥ VGPR being 91%. Of the 19 evaluable patients with cardiac involvement, 14 (74%) achieved organ response. Of the 13 evaluable patients with renal involvement, 6 (46%) achieved organ response. With a median follow-up of 22 months, median time-to-next-treatment (TTNT) and overall survival (OS) were not reached. The 12- and 24-month TTNT rates were 74% and 56%, respectively. At data-cut-off, four patients had died, all from AL-related organ complications. The 12- and 24-month OS rates were 89% and 85%, respectively. Grade ≥3 adverse events occurred in 26% of patients, with 6% due to infections. Conclusion: These findings are encouraging for the use of venetoclax as salvage therapy post-dara failure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Yield of repeat blood cultures in acute myeloid leukemia patients with febrile neutropenia and bacteremia following allogeneic hematopoietic stem cell transplant.

Author

Sheu, Michael, Molina Garcia, Sofia, Shrivastava, Gautam, Patel, Meera, Mushtaq, Ali, Crilley, Thomas, Anwer, Faiz, and Majeed, Aneela

Subjects
HEMATOPOIETIC stem cell transplantation, HEMATOPOIETIC stem cells, ACUTE myeloid leukemia, STEM cell transplantation, FEBRILE neutropenia
Abstract

Introduction: This study explored the efficacy of repeat blood cultures in bacteremic acute myeloid leukemia (AML) patients following allogeneic hematopoietic stem cell transplantation (HSCT). Methods: This was a retrospective study of AML patients who experienced febrile neutropenia (FN) and bacteremia following HSCT at the Taussig Cancer Center from January 1, 2019, to December 31, 2022. The primary endpoint was the rate of positive repeat blood cultures following initial positive blood culture. Results: Fifty patients were included in the study. There were 50 occurrences of FN with positive initial blood cultures that were diagnosed following HSCT. Fifty initial sets of blood cultures and 96 sets of repeat blood cultures were drawn between the 50 occurrences of FN. Twelve of 96 (12.5%) repeat blood culture sets were positive for a pathogen, which occurred over nine of 50 (18.0%) episodes of FN. Three of 96 (3.2%) repeat blood culture sets grew a pathogen that differed from the pathogen that grew in the preceding positive blood culture. Conclusion: Among bacteremic AML patients in the post‐HSCT period, the yield of repeat blood cultures for detecting previously detected and new pathogens was low. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Author

Gagelmann, Nico, primary, Dima, Danai, additional, Merz, Maximilian, additional, Hashmi, Hamza, additional, Ahmed, Nausheen, additional, Tovar, Natalia, additional, Oliver-Caldés, Aina, additional, Stölzel, Friedrich, additional, Rathje, Kristin, additional, Fischer, Luise, additional, Born, Patrick, additional, Schäfer, Lisa, additional, Albici, Anca-Maria, additional, Schub, Natalie, additional, Kfir-Erenfeld, Shlomit, additional, Assayag, Miri, additional, Asherie, Nathalie, additional, Wulf, Gerald Georg, additional, Kharboutli, Soraya, additional, Müller, Fabian, additional, Shune, Leyla, additional, Davis, James A., additional, Anwer, Faiz, additional, Vucinic, Vladan, additional, Platzbecker, Uwe, additional, Ayuk, Francis, additional, Kröger, Nicolaus, additional, Khouri, Jack, additional, Gurnari, Carmelo, additional, McGuirk, Joseph, additional, Stepensky, Polina, additional, Abdallah, Al-Ola, additional, and Fernández de Larrea, Carlos, additional

Published
2024
Full Text
View/download PDF

38. The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023

Author

Atallah, Rawan, primary, Saif, Md Saiful Islam, additional, Danai, Dima, additional, Shrestha, Anuj, additional, Anwer, Faiz, additional, Mushtaq, Muhammad Umair, additional, Lutfi, Forat, additional, Shune, Leyla, additional, Hashmi, Hamza, additional, Ganguly, Siddhartha MD, additional, McGuirk, Joseph P, additional, Atrash, Shebli, additional, Abdallah, Al-Ola, additional, Banerjee, Rahul, additional, Ahmed, Nausheen, additional, and Logan, Emerson, additional

Published
2024
Full Text
View/download PDF

39. Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma-1 Trial Eligibility Criteria: A Real-World Multicenter Study from the US Myeloma Innovations Research Collaborative (USMIRC)

Author

Dima, Danai, primary, Rashid, Aliya, additional, Davis, James, additional, Awada, Hussein, additional, Abdallah, Al-Ola, additional, DeJarnette, Shaun, additional, Shune, Leyla, additional, Khouri, Jack, additional, Hashmi, Hamza, additional, McGuirk, Joseph P, additional, Anwer, Faiz, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

40. A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients

Author

Wesson, William, primary, Dima, Danai, additional, Davis, James, additional, Rashid, Aliya, additional, Furqan, Fateeha, additional, Saif, Md Saiful Islam, additional, Logan, Emerson, additional, McGann, Mary, additional, Tabak, Carine, additional, Hazlett, Liz, additional, Lutfi, Forat, additional, Mushtaq, Muhammad Umair, additional, Hoffmann, Marc, additional, Abdallah, Al-Ola, additional, Anwer, Faiz, additional, Hamadani, Mehdi, additional, McGuirk, Joseph P, additional, Hashmi, Hamza, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

42. Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Treated with CAR T-Cell Therapies.

Author

Mian, Agrima, primary, Dima, Danai, additional, Hamilton, Betty K., additional, Winter, Allison, additional, Khouri, Jack, additional, Williams, Louis, additional, Raza, Shahzad, additional, Jagadeesh, Deepa, additional, Gerds, Aaron T., additional, Dean, Robert M., additional, Sobecks, Ronald M., additional, Kalaycio, Matt E., additional, Brunstein, Claudio G., additional, Sauter, Craig S, additional, Anwer, Faiz, additional, Hill, Brian T., additional, and Caimi, Paolo, additional

Published
2024
Full Text
View/download PDF

43. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)

Author

Dima, Danai, primary, Davis, James, additional, Ahmed, Nausheen, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher Sun, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Hashmi, Hamza, additional, and Abdallah, Al-Ola, additional

Published
2024
Full Text
View/download PDF

49. Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning

Author

Iftikhar, Raheel, Chaudhry, Qamar un Nisa, Mahmood, Syed Kamran, Ghafoor, Tariq, Satti, Humayun Shafique, Shahbaz, Nighat, Khan, Mehreen Ali, Khattak, Tariq Azam, Shamshad, Ghassan Umair, Rehman, Jahanzeb, Farhan, Muhammad, Humayun, Saima, Risalat, Amina, Wahab, Ahsan, Satti, Tariq Mehmood, Anwer, Faiz, and Ahmed, Parvez

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results